Shrila Rajendran
Overview
Explore the profile of Shrila Rajendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sinha S, Callow B, Farfel A, Roy S, Chen S, Masotti M, et al.
J Clin Invest
. 2024 Oct;
134(24).
PMID: 39480488
Estrogen receptor-positive (ER+) breast cancer commonly disseminates to bone marrow, where interactions with mesenchymal stromal cells (MSCs) shape disease trajectory. We modeled these interactions with tumor-MSC co-cultures and used an...
2.
Humphries B, Zhang A, Buschhaus J, Bevoor A, Farfel A, Rajendran S, et al.
iScience
. 2023 May;
26(6):106788.
PMID: 37235049
Mitochondria produce reactive oxygen species (ROS), which function in signal transduction. Mitochondrial dynamics, encompassing morphological shifts between fission and fusion, can directly impact ROS levels in cancer cells. In this...
3.
Sinha S, Callow B, Farfel A, Roy S, Chen S, Rajendran S, et al.
bioRxiv
. 2023 Mar;
PMID: 36993616
Estrogen receptor-positive (ER+) breast cancer commonly disseminates to bone marrow, where interactions with mesenchymal stromal cells (MSCs) shape disease trajectory. We modeled these interactions with tumor-MSC co-cultures and used an...
4.
Buschhaus J, Rajendran S, Chen S, Wharram B, Bevoor A, Cutter A, et al.
Mol Cancer Res
. 2023 Feb;
21(5):458-471.
PMID: 36735350
Implications: This study reveals how MSCs reprogram metabolism of ER+ breast cancer cells and point to MCT4 as potential therapeutic target to overcome resistance to antiestrogen drugs.
5.
Buschhaus J, Rajendran S, Humphries B, Cutter A, Muniz A, Ciavattone N, et al.
Oncogene
. 2022 Jun;
41(29):3705-3718.
PMID: 35732800
Patients with estrogen receptor-positive (ER+) breast cancer, the most common subtype, remain at risk for lethal metastatic disease years after diagnosis. Recurrence arises partly because tumor cells in bone marrow...
6.
Humphries B, Aliabouzar M, Quesada C, Bevoor A, Ho K, Farfel A, et al.
Adv Healthc Mater
. 2022 Feb;
11(10):e2101672.
PMID: 35106975
Cancer cells continually sense and respond to mechanical cues from the extracellular matrix (ECM). Interaction with the ECM can alter intracellular signaling cascades, leading to changes in processes that promote...
7.
Buschhaus J, Humphries B, Eckley S, Robison T, Cutter A, Rajendran S, et al.
Oncogene
. 2020 Jul;
39(34):5649-5662.
PMID: 32678295
Estrogen receptor-positive (ER+) breast cancer can recur up to 20 years after initial diagnosis. Delayed recurrences arise from disseminated tumors cells (DTCs) in sites such as bone marrow that remain...
8.
Humphries B, Buschhaus J, Chen Y, Haley H, Qyli T, Chiang B, et al.
Mol Cancer Res
. 2019 Feb;
17(5):1142-1154.
PMID: 30718260
Migration and invasion of cancer cells constitute fundamental processes in tumor progression and metastasis. Migratory cancer cells commonly upregulate expression of plasminogen activator inhibitor 1 (PAI1), and PAI1 correlates with...